Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival versus the general population and often experience burdensome signs and symptoms that reduce qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Mesa, Ruben A., Livingston, Robert A., Hu, Wilson, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373260/
https://www.ncbi.nlm.nih.gov/pubmed/37501130
http://dx.doi.org/10.1186/s13045-023-01471-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373260/
https://www.ncbi.nlm.nih.gov/pubmed/37501130
http://dx.doi.org/10.1186/s13045-023-01471-z

Ejemplares similares